Johnson & Johnson Company News

J&J eyes US nod for Caplyta in bipolar mania after second trial win - Reuters

J&J eyes US nod for Caplyta in bipolar mania after second trial win Reuters

Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs - PA Department of Community & Economic Development (.gov)

Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs PA Department of Community & Economic Development (.gov)

Johnson & Johnson's venture arm backs Francis Medical for prostate cancer push - Dealroom

Johnson & Johnson's venture arm backs Francis Medical for prostate cancer push Dealroom

J&J Backs Psychedelic-Inspired Biotech in $100 Million Round - Bloomberg.com

J&J Backs Psychedelic-Inspired Biotech in $100 Million Round Bloomberg.com

Johnson & Johnson Ordered to Pay $34 Million to Mesothelioma Victim’s Family - Mesothelioma.net

Johnson & Johnson Ordered to Pay $34 Million to Mesothelioma Victim’s Family Mesothelioma.net

Johnson & Johnson is backing a psychedelic-inspired depression startup in a $100 million round - Quartz

Johnson & Johnson is backing a psychedelic-inspired depression startup in a $100 million round Quartz

Johnson & Johnson’s Caplyta meets endpoints in bipolar mania study - Investing.com

Johnson & Johnson’s Caplyta meets endpoints in bipolar mania study Investing.com

Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth - Yahoo Finance

Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth Yahoo Finance

Pharma Giants Race to Develop New Prostate Cancer Treatments Targeting Resistant Tumors - 조선일보

Pharma Giants Race to Develop New Prostate Cancer Treatments Targeting Resistant Tumors 조선일보

Q3 Earnings Season Winners: 3 Companies Raising Guidance - TradingView

Q3 Earnings Season Winners: 3 Companies Raising Guidance TradingView

Johnson & Johnson Shares Patient Experience Data from Phase 2 DA - GuruFocus

Johnson & Johnson Shares Patient Experience Data from Phase 2 DA GuruFocus

Johnson & Johnson announces new Phase 2 nipocalimab study data in... - Quantisnow

Johnson & Johnson announces new Phase 2 nipocalimab study data in... Quantisnow

Johnson & Johnson's drug improved mania symptoms by Day 3 in a second study. - Stock Titan

Johnson & Johnson's drug improved mania symptoms by Day 3 in a second study. Stock Titan

6 ways Johnson & Johnson is using AI to help advance healthcare - Johnson & Johnson

6 ways Johnson & Johnson is using AI to help advance healthcare Johnson & Johnson

J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial - Yahoo Finance

J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial Yahoo Finance

Johnson and Johnson stock hits all-time high of 282.03 USD - Investing.com

Johnson and Johnson stock hits all-time high of 282.03 USD Investing.com

How Did Johnson & Johnson Raise Its Outlook Despite a Talc Charge? - Kalkine Media

How Did Johnson & Johnson Raise Its Outlook Despite a Talc Charge? Kalkine Media

Johnson & Johnson's JJDC Joins $100M Funding Round for Delix The - GuruFocus

Johnson & Johnson's JJDC Joins $100M Funding Round for Delix The GuruFocus

Johnson & Johnson stock gets deeper prostate-cancer response signal - ad-hoc-news.de

Johnson & Johnson stock gets deeper prostate-cancer response signal ad-hoc-news.de

Johnson and Johnson Earnings Report | 2026 Q3 Infographic - Johnson & Johnson

Johnson and Johnson Earnings Report | 2026 Q3 Infographic Johnson & Johnson

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September - Johnson & Johnson

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September Johnson & Johnson

Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence - Johnson & Johnson

Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence Johnson & Johnson

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida - Johnson & Johnson

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida Johnson & Johnson

Johnson & Johnson makes WSJ 2026 Best Companies for the Future list - Johnson & Johnson

Johnson & Johnson makes WSJ 2026 Best Companies for the Future list Johnson & Johnson

Johnson & Johnson Continues Investing in Pennsylvania, Further Cementing the Commonwealth as a Global Leader in Life Science Innovation - PA Department of Community & Economic Development (.gov)

Johnson & Johnson Continues Investing in Pennsylvania, Further Cementing the Commonwealth as a Global Leader in Life Science Innovation PA Department of Community & Economic Development (.gov)

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania - Johnson & Johnson

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania Johnson & Johnson

Johnson & Johnson - Britannica

Johnson & Johnson Britannica

Johnson & Johnson named a 2026 Fortune World’s Most Admired Company - Johnson & Johnson

Johnson & Johnson named a 2026 Fortune World’s Most Admired Company Johnson & Johnson

What you need to know about Johnson & Johnson’s fourth-quarter and full-year 2025 earnings report - Johnson & Johnson

What you need to know about Johnson & Johnson’s fourth-quarter and full-year 2025 earnings report Johnson & Johnson

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line - Johnson & Johnson

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line Johnson & Johnson

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer - Johnson & Johnson

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer Johnson & Johnson

Suppliers - Johnson & Johnson

Suppliers Johnson & Johnson

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - Johnson & Johnson

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use Johnson & Johnson